iBio, Inc.
Close on Oct 19, 2026
- Market cap
- $110.48M
- P/E (TTM)
- –
- Dividend yield
- –
About iBio
Pharmaceutical Preparations, SIC 2834
iBio, Inc. is a clinical-stage biotechnology company that develops precision antibody therapeutics for obesity, cardiometabolic conditions, and cardiopulmonary diseases. Operating through an integrated artificial intelligence and machine learning drug discovery platform, the company designs biologic candidates directed against complex, hard-to-drug targets. Its pipeline includes IBIO-600, an anti-myostatin antibody in clinical development, alongside preclinical candidates such as IBIO-610, an Activin E antibody, and IBIO-800, a bispecific antibody for cardiopulmonary indications. Additionally, the company develops T-cell engaging bispecific antibodies for oncology and collaborates with partners such as AstralBio on engineered amylin receptor agonist antibodies.
The company conducts research and development activities at its laboratory facility in San Diego, California. Clinical development for its lead candidate has extended internationally, with clinical trial activity and participant enrollment initiated in Australia. The text does not disclose the location of corporate headquarters, total facilities, or commercial customer segments.
Summary of the business section of iBio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- iBio, Inc.
- Headquarters
- New York, NY
- Address
- 600 Madison Avenue, Suite 1601 10022-1737
- Phone
- (302) 355-0650
- Employees
- 23, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- GRASSI & Co., CPAs, P.C., Jericho, New York
Stock & identifiers
- Ticker
- IBIO
- Exchange
- Nasdaq
- IPO date
- Aug 19, 2008
- Shares outstanding
- 64M, Aug 27, 2026
- Public float
- $57.51M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Nov 29, 2023; 1-for-20 reverse, Nov 29, 2023; 1-for-25 reverse, Oct 10, 2022; 1-for-25 reverse, Oct 7, 2022; 1-for-10 reverse, Sep 18, 2018; 1-for-10 reverse, Jun 11, 2018
- SEC CIK
- 1420720
- CUSIP
- 451033708
- ISIN
- US4510337086
- LEI
- 529900EW4RXUITGKUT34
- EIN
- 26-2797813
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Martin Brenner | See Remarks, Director | 30,652 |
| Molly Carr | Chief Medical Officer | – |
| Marc Banjak | Chief Legal Officer | 25,000 |
| Felipe Duran | Chief Financial Officer | 35,974 |
| Elizabeth Stoner | Director | – |
| Antonio Bernardino Guimaraes Parada | Director | 183,823 |
| Evert B. Schimmelpennink | Director | – |
| Alexandra Kropotova | Director | – |
| William D. Clark | Director | 1,838 |
| Gary Sender | Director | 9,191 |
| David Arkowitz | Director | 18,382 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Dr. Martin B. Brenner | $2.14M | $2.31M | $1.02M | $14 | – |
| FY2025 Current Chief Executive Officer Martin Brenner | $1.51M | $621.72K | $741.49K | $6 | – |
| FY2025 Dr. Martin B. Brenner | $1.51M | $621.72K | $741.49K | $6 | – |
| FY2024 Current Chief Executive Officer Martin Brenner | $1.27M | $1.18M | $761.87K | $17 | – |
| FY2024 Dr. Martin B. Brenner | $1.27M | $1.18M | $761.87K | $17 | – |
| FY2023 Current Chief Executive Officer Martin Brenner | $1.07M | $629.45K | $630.74K | $9 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of August 27, 2026, we had 23 employees, all of which are full-time employees, in addition to two strategic consultants.”
Corporate history
Events identified from SEC filings